PP405: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions for PP405 have not been publicly disclosed. Clinical trial protocols likely specify controlled room temperature storage.
Protocol Quick-Reference
Androgenetic alopecia (male and female pattern hair loss)
Dosing
Amount
0.05% topical gel
Frequency
Once daily
Duration
4 weeks (Phase 2a)
Administration
Route
TopicalTiming
Apply once daily to affected scalp areas; results observed at 8 weeks (4 weeks after treatment ended), suggesting sustained biological effect
Cycle
Duration
4 weeks
Repeatable
Yes
โ๏ธ Suggested Bloodwork (2 tests)
Scalp assessment and hair density measurement
When: Baseline
Why: Document baseline hair density and condition
Scalp assessment and hair density measurement
When: 8 weeks
Why: Evaluate hair regrowth response
๐ก Key Considerations
- โInvestigational drug: not approved by any regulatory authority and not commercially available
- โNo systemic absorption detected in clinical trials; topical-only mechanism
- โNovel mechanism independent of hormonal pathways (MPC inhibition, not DHT-related)
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Androgenetic Alopecia (Phase 2a Clinical Trial) | 0.05% PP405 topical gel applied to affected scalp areas once daily. | Once daily | 4 weeks of active treatment in the Phase 2a trial, with observation continuing to 12 weeks. Optimal long-term treatment duration has not been established. | PP405 is an investigational drug. This dosing information reflects the clinical trial protocol and is not a prescribing recommendation. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Not applicable. PP405 is supplied as a ready-to-use 0.05% topical gel formulation. No mixing, reconstitution, or preparation is required.
Recommended Injection Sites
- โNot applicable. PP405 is a topical gel applied directly to the scalp. It is not an injectable product.
๐งStorage Requirements
Storage conditions for PP405 have not been publicly disclosed. Clinical trial protocols likely specify controlled room temperature storage.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Important Notice#
PP405 is an investigational drug currently in clinical trials. It is not approved by any regulatory authority and is not available for purchase or prescription. The dosing information below reflects the clinical trial protocol only.
Clinical Trial Dosing#
Phase 2a Protocol (NCT06393452)#
| Parameter | Details |
|---|---|
| Formulation | 0.05% PP405 topical gel |
| Comparator | Vehicle (placebo) gel |
| Application | Once daily to affected scalp areas |
| Treatment duration | 4 weeks |
| Observation period | 12 weeks total |
| Study population | 78 men and women with androgenetic alopecia |
Application Instructions (from clinical trial)#
- Apply the 0.05% PP405 gel to the affected areas of the scalp
- Apply once daily (timing not specified as morning or evening)
- Allow the gel to absorb into the scalp
- Continue for the prescribed treatment duration
Key Observations#
The Phase 2a trial used a relatively short 4-week treatment period, which is notable because:
- Standard hair loss treatments (minoxidil, finasteride) typically require 3-6 months of continuous use before visible results
- PP405 showed measurable increases in hair density at the 8-week assessment (4 weeks after treatment ended)
- This suggests a sustained biological effect from stem cell activation that continues beyond the active treatment period
- Optimal treatment duration, long-term maintenance protocols, and whether continuous use provides additional benefit remain to be determined in Phase 3 trials
Formulation Characteristics#
PP405 is formulated as a topical gel at 0.05% concentration, designed for:
- Adequate penetration through the scalp to reach hair follicle stem cells
- No detectable systemic absorption (confirmed in Phase 1 and Phase 2a pharmacokinetic studies)
- Cosmetic acceptability for daily scalp application
- Compatibility with diverse skin phototypes and hair textures (the Phase 2a trial enrolled a diverse patient population)
Dosing Context#
PP405 belongs to the Skin category of research peptides. Dosing protocols for PP405 are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.
Research Protocols#
The following dosing protocols have been documented in clinical research for PP405:
Androgenetic Alopecia (Phase 2a Clinical Trial)#
Dose: 0.05% PP405 topical gel applied to affected scalp areas once daily.
Frequency: Once daily
Duration: 4 weeks of active treatment in the Phase 2a trial, with observation continuing to 12 weeks. Optimal long-term treatment duration has not been established.
PP405 is an investigational drug. This dosing information reflects the clinical trial protocol and is not a prescribing recommendation.
Reconstitution and Preparation#
Not applicable. PP405 is supplied as a ready-to-use 0.05% topical gel formulation. No mixing, reconstitution, or preparation is required.
Injection Sites#
Recommended injection sites for PP405 include:
- Not applicable. PP405 is a topical gel applied directly to the scalp. It is not an injectable product.
Site rotation is recommended to minimize local tissue reactions and ensure consistent absorption.
Storage Requirements#
Storage conditions for PP405 have not been publicly disclosed. Clinical trial protocols likely specify controlled room temperature storage.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About PP405
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.